openPR Logo
Press release

Global Biosimilars Market and Forecast (By Product Type, Applications, Country Wise and Companies) to 2021 and Biosimilars Approved and Pipeline Analysis

12-01-2016 12:02 PM CET | Health & Medicine

Press release from: ReportsWorldwide

Global Biosimilars Market and Forecast (By Product Type,

ReportsWorldwide has announced the addition of a new report title Global Biosimilars Market and Forecast (By Product Type, Applications, Country Wise and Companies) to 2021 and Biosimilars Approved and Pipeline Analysis to its growing collection of premium market research reports.

The biosimilars are poised to capture an unprecedented position in the biopharmaceutical industry driven by an increased extent of adoption and growing investment and deal making activity globally.

The global biosimilars market is predicted to cross US$ 25 Billion mark by 2020. With the continuous increasing demand for biologics, manufacturers are looking for novel strategies that will help them attain maximum returns on investment.

Biosimilars are seen as the key weapon to curbing soaring healthcare costs globally. The major factor that is driving the market for biosimilars industry is the fact that major biologics are nearing the patent cliff. Further, the lower cost of these drugs as compared to the patented biologics, the increasing encumbrance to curb healthcare costs globally, increasing nationwide government initiatives, and the strong pipeline for the biosimilar drugs is expected to fuel the biosimilars industry.

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/global-biosimilars-market-and-forecast-by-product-type-applications-country-wise-and-companies-to-2021-and-biosimilars-approved-and-pipeline-analysis

Key Highlights of the Report

Biosimilars Market - By Product Type

• The erythropoietin (EPO) captures maximum share of the global biosmilars market.
• The Granulocyte- Colony Stimulating Factor (G-CSF) market is expected to cross US$ 6 Billion mark by 2021.
• The Human Growth Hormone (HGH) biosimilars market is expected to grow with a double digit CAGR during the period 2016 - 2021.
• The monoclonal antibody is expected to show the highest growth rate during the period 2016 - 2021.
• The insulin and interferon product segment each accounted for single digit share of the global biosimilars market respectively in 2015.
Biosimilars Market - By Applications
• Among various application segments of biosimilar market, blood disorders and oncology together accounted for over 55% share of the global biosimilars market in 2015.
• Growth hormone deficiencies application is expected to show double digit CAGR during the period 2016 - 2021.
• The chronic and autoimmune disorders captured XX% share of the biosmilars market in 2015.

Biosimilars Market - By Country Wise

• The market for biosimilars in the U.S. has gained momentum after the launch of Novartis’ Zarxio in September 2015.
• In the European countries, Germany is at the forefront with around XX% share of the biosimilars market in 2015 followed by France with XX% share in the same year.
• China accounted for XX% share of the global biosimilar market in 2015.
• India is seen as a key player in the biosimilar space with an exceptionally high number of approvals granted in the last decade compared to the global average.
• South Korea captured XX% of the global biosimilar market in 2015 being closely followed by Brazil with XX% share in the same year.

This 177 Page report with 74 Figures and 27 Tables is analyzed from 6 viewpoints:

1. Global Biosimilars Market and Forecast - By Product Type
2. Global Biosimilars Market and Forecast - By Applications
3. Global Biosimilars Market and Forecast - By Country Wise
4. Global Biosimilars Company - Profile, Revenue, Approved and Pipeline Biosimilars Analysis
5. Country with Biosimilar Guideline and Published Year
6. Global Biosimilars Market - Driving Factors and Challenges

Global Biosimilars Market and Forecast - 7 Product Types Covered

1. Erythropoietin (EPO)
2. Human Growth Hormone (HGH)
3. Granulocyte- Colony Stimulating Factor (G-CSF)
4. Monoclonal Antibody (mAb)
5. Insulin
6. Interferon (IFN)
7. Others

Global Biosimilars Market and Forecast - 5 Applications Covered

1. Oncology
2. Blood Disorders
3. Growth Hormone Deficiencies
4. Chronic and Autoimmune Disorders
5. Other Applications
Global Biosimilars Market and Forecast - 16 Countries Covered
1. United States
2. Canada
3. Argentina
4. Germany
5. France
6. Italy
7. Spain
8. United Kingdom
9. China
10. Japan
11. India
12. South Korea
13. Australia
14. Brazil
15. Mexico
16. Rest of the World

Global Biosimilars Company Analysis - 13 Companies Covered

1. Biocad
2. Celltrion Inc.
3. Dong-A Socio Group
4. Pfizer Inc.
5. Intas Pharmaceuticals Ltd.
6. Sandoz International GmbH - A Novartis Company
7. Stada Arzneimittel AG
8. Teva Pharmaceutical Industries Ltd
9. Amgen Inc.
10. Biocon
11. Dr. Reddy’s Laboratories
12. Mylan
13. Merck KGaA

To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=2583

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Biosimilars Market and Forecast (By Product Type, Applications, Country Wise and Companies) to 2021 and Biosimilars Approved and Pipeline Analysis here

News-ID: 389734 • Views:

More Releases from ReportsWorldwide

World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence
New report explores the Gene Editing Market : Ushering The Next Breakthrough in Regenerative Medicine
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports. Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors. Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that
Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports. This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers: • CommScope/Airvana • Comba Telecom • Ericsson • Huawei Technologies • Nokia • SpiderCloud • ZTE Corporation This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021. To view a detailed description and Table of

More Releases for Biosimilar

Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030." Get
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031." The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of